Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract 1168: ADAR1 synthetic lethality in BRCA1/2-mutant tumors defines autocrine interferon poisoning as a targetable vulnerability of cancer cells

Cancer Res (2025) 85 (8_Supplement_1): 1168.

https://doi.org/10.1158/1538-7445.AM2025-1168

Published: 21 April 2025

View articletitled, Abstract 1168: ADAR1 synthetic lethality in BRCA1/2-mutant tumors defines autocrine interferon poisoning as a targetable vulnerability of cancer cells

Journal Articles

Abstract PO2-18-11: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

Cancer Res (2024) 84 (9_Supplement): PO2-18-11.

https://doi.org/10.1158/1538-7445.SABCS23-PO2-18-11

Published: 02 May 2024

View articletitled, Abstract PO2-18-11: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

Journal Articles

Abstract P2-02-07: Patients’ selection of daily timing of oral intake of adjuvant hormonotherapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial

Sylvie Giacchetti, Anne-Sophie Hamy, Thomas Bachelot, Jérôme Lemonnier, Fabrice Andre, David A. Cameron, Judith Bliss, Sylvie Chabaud, Anne-Claire Hardy-Bessard, Magali Lacroix-Triki, Jean-Luc Canon, Hervé R. Bonnefoi, Mario Campone, Paul Cottu, Florence Dalenc, Annabelle Ballesta, Francis Lévi, Enora Laas

Cancer Res (2023) 83 (5_Supplement): P2-02-07.

https://doi.org/10.1158/1538-7445.SABCS22-P2-02-07

Published: 01 March 2023

View articletitled, Abstract P2-02-07: Patients’ selection of daily timing of oral intake of adjuvant hormonotherapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial

Journal Articles

Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

Cancer Res (2022) 82 (4_Supplement): PD8-02.

https://doi.org/10.1158/1538-7445.SABCS21-PD8-02

Published: 15 February 2022

View articletitled, Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

Journal Articles

Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)

Cancer Res (2022) 82 (4_Supplement): PD9-08.

https://doi.org/10.1158/1538-7445.SABCS21-PD9-08

Published: 15 February 2022

View articletitled, Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)

Journal Articles

Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study

Cancer Res (2020) 80 (4_Supplement): P5-02-04.

https://doi.org/10.1158/1538-7445.SABCS19-P5-02-04

Published: 15 February 2020

View articletitled, Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study

Journal Articles

Abstract 5238: Characterization of the enzyme generating the cholesterol metabolite and tumor suppressor dendrogenin A in the breast and its deregulations in breast cancer

Cancer Res (2018) 78 (13_Supplement): 5238.

https://doi.org/10.1158/1538-7445.AM2018-5238

Published: 01 July 2018

View articletitled, Abstract 5238: Characterization of the enzyme generating the cholesterol metabolite and tumor suppressor dendrogenin A in the breast and its deregulations in breast cancer

Journal Articles

Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial

Monica Arnedos, Bianca Cheaib, Mohamed Amine Bayar, Stefan Michiels, Veronique Scott, Julien Adam, Valerie Leroux-Kozal, Virginie Marty, Chafika Mazouni, Benjamin Sarfati, Ivan Bieche, David Gentien, Suzette Delaloge, Magali Lacroix-Triki, Fabrice Andre

Cancer Res (2016) 76 (14_Supplement): CT041.

https://doi.org/10.1158/1538-7445.AM2016-CT041

Published: 15 July 2016

View articletitled, Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial

Journal Articles

Abstract 1165: Identification of a cholesterol onco-metabolite, promoter of tumor in breast cancers, and of the enzyme involved in its biosynthesis

Maud Voisin, Philippe de Medina, Michael R. Paillasse, Magali Lacroix-Triki, Florence Dalenc, Marc Poirot, Sandrine Silvente-Poirot

Cancer Res (2015) 75 (15_Supplement): 1165.

https://doi.org/10.1158/1538-7445.AM2015-1165

Published: 01 August 2015

View articletitled, Abstract 1165: Identification of a cholesterol onco-metabolite, promoter of tumor in breast cancers, and of the enzyme involved in its biosynthesis

Journal Articles

Abstract OT3-3-02: ASTER 70s UNICANCER phase III trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?

Cancer Res (2015) 75 (9_Supplement): OT3-3-02.

https://doi.org/10.1158/1538-7445.SABCS14-OT3-3-02

Published: 01 May 2015

View articletitled, Abstract OT3-3-02: ASTER 70s UNICANCER phase III trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?

Journal Articles

Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

Pierre Zindy, Yann Bergé, Ben Allal, Thomas Filleron, Sandra Pierredon, Anne Cammas, Samantha Beck, Loubna Mhamdi, Li Fan, Gilles Favre, Jean-Pierre Delord, Henri Roché, Florence Dalenc, Magali Lacroix-Triki, Stéphan Vagner

Cancer Res (2011) 71 (12): 4068–4073.

https://doi.org/10.1158/0008-5472.CAN-11-0420

Published: 14 June 2011

View articletitled, Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

Includes: Supplementary data

Journal Articles

PTPL1/PTPN13 Regulates Breast Cancer Cell Aggressiveness through Direct Inactivation of Src Kinase

Murielle Glondu-Lassis, Mathilde Dromard, Magali Lacroix-Triki, Philippe Nirdé, Carole Puech, Dora Knani, Dany Chalbos, Gilles Freiss

Cancer Res (2010) 70 (12): 5116–5126.

https://doi.org/10.1158/0008-5472.CAN-09-4368

Published: 14 June 2010

View articletitled, PTPL1/PTPN13 Regulates Breast Cancer Cell Aggressiveness through Direct Inactivation of Src Kinase

Includes: Supplementary data

Journal Articles

Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis

Martin Dutertre, Magali Lacroix-Triki, Keltouma Driouch, Pierre de la Grange, Lise Gratadou, Samantha Beck, Stefania Millevoi, Jamal Tazi, Rosette Lidereau, Stephan Vagner, Didier Auboeuf

Cancer Res (2010) 70 (3): 896–905.

https://doi.org/10.1158/0008-5472.CAN-09-2703

Published: 31 January 2010

View articletitled, Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis

Includes: Supplementary data

Journal Articles

Widespread Estrogen-Dependent Repression of microRNAs Involved in Breast Tumor Cell Growth

Gérard Maillot, Magali Lacroix-Triki, Sandra Pierredon, Lise Gratadou, Sabine Schmidt, Vladimir Bénès, Henri Roché, Florence Dalenc, Didier Auboeuf, Stefania Millevoi, Stéphan Vagner

Cancer Res (2009) 69 (21): 8332–8340.

https://doi.org/10.1158/0008-5472.CAN-09-2206

Published: 28 October 2009

View articletitled, Widespread Estrogen-Dependent Repression of microRNAs Involved in Breast Tumor Cell Growth

Includes: Supplementary data

Journal Articles

Deregulated DNA Polymerase β Induces Chromosome Instability and Tumorigenesis

Valérie Bergoglio, Marie-Jeanne Pillaire, Magali Lacroix-Triki, Brigitte Raynaud-Messina, Yvan Canitrot, Anne Bieth, Michèle Garès, Michel Wright, Georges Delsol, Lawrence A. Loeb, Christophe Cazaux, Jean-Sébastien Hoffmann

Cancer Res (2002) 62 (12): 3511–3514.

Published: 01 June 2002

View articletitled, Deregulated DNA Polymerase β Induces Chromosome Instability and Tumorigenesis

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 1168: ADAR1 synthetic lethality in BRCA1/2-mutant tumors defines autocrine interferon poisoning as a targetable vulnerability of cancer cells

Abstract PO2-18-11: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

Abstract P2-02-07: Patients’ selection of daily timing of oral intake of adjuvant hormonotherapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial

Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)

Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study

Abstract 5238: Characterization of the enzyme generating the cholesterol metabolite and tumor suppressor dendrogenin A in the breast and its deregulations in breast cancer

Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial

Abstract 1165: Identification of a cholesterol onco-metabolite, promoter of tumor in breast cancers, and of the enzyme involved in its biosynthesis

Abstract OT3-3-02: ASTER 70s UNICANCER phase III trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?

Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

PTPL1/PTPN13 Regulates Breast Cancer Cell Aggressiveness through Direct Inactivation of Src Kinase

Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis

Widespread Estrogen-Dependent Repression of microRNAs Involved in Breast Tumor Cell Growth

Deregulated DNA Polymerase β Induces Chromosome Instability and Tumorigenesis

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only